COMPASS Pathways plc (CMPS): Total Assets
$210.35M
As of 2025-12-31
$504.56M
As of 2026-06-30
+2.2%
3-year compound annual growth
+0.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $210.35M | -1.6% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $213.67M | -22.6% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $275.99M | +39.9% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $197.29M | -34.4% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $300.90M | +47.9% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $203.46M | +528.2% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $32.39M | n/a | 2021-03-09, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $210.35M | -1.6% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $216.30M | +1.4% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $219.47M | -10.2% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $219.57M | +101.6% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $200.46M | -29.8% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $198.10M | -30.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $225.23M | -43.3% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $225.87M | -2.9% |
Compare CMPS, PBYI, SIGA, ABEO side by side · Screen every company in Pharmaceutical Preparations ↗